Clinical Trial Search

Primary: Calculation of M Scores and HCC Probability Scores — 1.113; 1.159; 1.797; 1.707 units on a scale

Primary: Number of Subjects With Overall Survival — 16; 4; 34; 24 Participants — p=0.536

Primary: Incidence of Dose Limiting Toxicities (DLTs) — 1; 1; 2 Participants

Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM

Primary: Phase 1b: Number of Participants Experiencing Dose Limiting Toxicity (DLT) According to National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) for Adverse Events…

Primary: HCC Screening Completion — 27.6; 54.5; 54.1 Percentage of participants

Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) — 1; 0 Participants

Primary: Disease Control Rate (DCR) at 16 Weeks for Patients Treated With Guadecitabine After Failure of Sorafenib — 25.0; 24.4 percentage of patients

Primary: Time to Progression (TTP) — 164; 112 days

Primary: Number of Subjects Who Completed 24 Weeks of Therapy — 0; 1 Participants

Primary: Phase 1b: Number of Participants Experiencing Dose Limiting Toxicity — 0; 0; 0 Participants

Primary: One-Year Overall Survival Rate — 16 Participants

Primary: Residual Disease on CEUS Imaging. — 19 lesions

Primary: Progression-Free Survival(PFS) — 5.7; 2.7 months — p=<0.001

Primary: Number of Participants With Objective Response Rate — 20; 9; 0; 1 Participants

Primary: Overall Survival (OS) — 8.51; 7.29 Months — p=0.0199

Primary: Objective Response Rate — 11.9; 16.7 percentage of participants

Primary: Progression — 11 participants

Primary: Participants Without Recurrence (Disease-free). — 16; 28 Participants

Primary: Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up. — 6.7 months

Primary: Number of Participants With Objective Tumor Response at 6 Months by MRI (Magnetic Resonance Imaging) — 75; 73 participants

Primary: Overall Survival — 289; 259 Days

Primary: Number of Patients Who Experience Dose Limiting Toxicities by Dose Level — 1; 0 Participants

Primary: Rate of Adverse Events (AE) ≥ Grade 3 (CTCAE 5.0) Excluding Palmar-plantar Erythrodysesthesia — 16 Participants

Primary: 6 Month Progression Free Survival (PFS) — 2.8; NA Months

Primary: Diagnostic Value Evaluation for HCC — 62; 80; 86; 100 percent

Primary: Dose Limiting Toxicity — 0; 0; 0 Participants

Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability. — 16; 5 Participants

Primary: Number of Adverse Events — 12; 2; 8; 4 events

Primary: Disease Control Rate (DCR) in Study Participants — 46 percentage of participants